Relfydess (relabotulinumtoxinA) is a ready-to-use, complex-free liquid neurotoxin with Phase 3 data supporting rapid onset and sustained improvement for glabellar lines and crow’s feet in many patients. Here’s what aesthetic providers need to know about its clinical profile—and how to prepare their practice before adding it to the menu.
The FDA approval of RADIESSE for décolletage wrinkle treatment marks the first time a biostimulatory filler has been cleared for both facial and body indications in the United States. This 2026 clinical guide covers every injectable and non-injectable option available — from SKINVIVE and Sculptra to fractional lasers and RF microneedling — with guidance on patient selection and combination protocols.
Many physicians and nurse practitioners are drawn to aesthetic medicine as a side hustle—but the reality involves more than a weekend course and a few injection sessions. This guide breaks down the true time commitment, startup costs, and income potential so you can decide if the trade-offs are right for you.
Many physicians and nurse practitioners are drawn to aesthetic medicine as a side hustle—but the reality involves more than a weekend course and a few injection sessions. This guide breaks down the true time commitment, startup costs, and income potential so you can decide if the trade-offs are right for you.
This article breaks down Botox pricing 2026 benchmarks so new aesthetic providers can avoid undercharging. Learn how to use memberships and value-based pricing to build a profitable injectable practice.
Ultrasound skin tightening is becoming a go‑to option in 2026 for patients who want better skin architecture without looking overfilled. This article explains how ultrasound skin tightening fits into GLP‑1 weight-loss plans, wedding timelines, and Q2 device strategy.
March 2026 brought meaningful advances in aesthetic medicine, from new FDA-approved options for managing GLP-1-related facial volume loss to strengthening clinical evidence for polynucleotide and exosome therapies. This roundup covers the developments most relevant to certified aesthetic providers, including new consensus guidance, shifting patient demographics, and an evolving regulatory landscape.
March 2026 delivered some of the most consequential GLP-1 news of the year — from a sweeping FDA enforcement action against telehealth compounders to the approval of Foundayo, the first oral GLP-1 with no food or water restrictions. Here’s what every provider needs to know this month.
Two oral GLP-1 medications for obesity are now FDA-approved — Eli Lilly’s Foundayo (orforglipron) and Novo Nordisk’s Wegovy pill (semaglutide 25 mg) — and they are meaningfully different. This clinical comparison breaks down the trial data, dosing requirements, and pricing so providers can have informed conversations with patients.
Insurance-based practice has become one of the leading structural drivers of physician burnout — but the solution is not a wellness seminar. For a growing number of physicians, cash-based aesthetic medicine is the deliberate exit strategy that removes the administrative burden and puts them back in control of their time and income.